Key Insights

Highlights

Success Rate

71% trial completion

Published Results

12 trials with published results (16%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

16.4%

12 terminated out of 73 trials

Success Rate

71.4%

-15.1% vs benchmark

Late-Stage Pipeline

1%

1 trials in Phase 3/4

Results Transparency

40%

12 of 30 completed with results

Key Signals

12 with results71% success12 terminated

Data Visualizations

Phase Distribution

63Total
Not Applicable (25)
Early P 1 (4)
P 1 (18)
P 2 (15)
P 3 (1)

Trial Status

Completed30
Active Not Recruiting15
Terminated12
Recruiting9
Withdrawn7

Trial Success Rate

71.4%

Benchmark: 86.5%

Based on 30 completed trials

Clinical Trials (73)

Showing 20 of 20 trials
NCT05243056Not ApplicableTerminated

A Quality of Life Intervention for Young African American Breast Cancer Survivors in Treatment

NCT05455658Phase 2Active Not Recruiting

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

NCT05049746Not ApplicableActive Not Recruiting

Identifying Decision Making Needs for Older Adult Women With Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy

NCT03218826Phase 1Completed

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

NCT04001829Phase 2Active Not Recruiting

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

NCT02918474Not ApplicableRecruiting

Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

NCT04678414Active Not Recruiting

Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer

NCT03939481Active Not Recruiting

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

NCT03786354Not ApplicableActive Not Recruiting

Intensity Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Treating Patients With Lymph-Node Positive Breast Cancer

NCT03725436Phase 1Completed

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

NCT05417308Early Phase 1Recruiting

Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer

NCT01334021Phase 2Active Not Recruiting

Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer

NCT05025059Not ApplicableActive Not Recruiting

Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer

NCT04090567Phase 2Recruiting

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

NCT04906200Not ApplicableActive Not Recruiting

Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors

NCT03707574Completed

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

NCT03505736Completed

Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer

NCT04481113Phase 1Completed

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

NCT06324240Phase 1Recruiting

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

NCT02971748Phase 2Active Not Recruiting

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

Scroll to load more

Research Network

Activity Timeline